Abstract |
Human immunodeficiency virus (HIV)-related CD8+ cutaneous pseudolymphoma (CD8+ cytotoxic T cell skin infiltrative disease) is an inflammatory process resulting from a massive infiltration of the skin by activated, oligoclonal, HIV-specific, cytotoxic T lymphocytes. Usually, CD8+ cutaneous pseudolymphoma affects patients with a deep immunosuppression, and is rare in patients with mild immunosuppression. In deeply immunocompromised patients, highly active antiretroviral therapy ( HAART) is considered as the first-line treatment. In contrast, the choice of therapy in moderately immunocompromised patients and/or patients already receiving HAART remains nonconsensual. We report a case of HIV-related CD8+ cutaneous pseudolymphoma in a moderately immunocompromised patient who was successfully and safely treated with methotrexate. We review the literature on HIV-related CD8+ pseudolymphoma and the use of methotrexate in HIV-positive patients.
|
Authors | S Ingen-Housz-Oro, E Sbidian, N Ortonne, D Penso-Assathiany, V Chambrin, M Bagot, H Bachelez, P Wolkenstein, O Chosidow |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 226
Issue 1
Pg. 15-8
( 2013)
ISSN: 1421-9832 [Electronic] Switzerland |
PMID | 23343593
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | Copyright © 2013 S. Karger AG, Basel. |
Chemical References |
- Dermatologic Agents
- Methotrexate
|
Topics |
- Antiretroviral Therapy, Highly Active
(methods)
- CD8-Positive T-Lymphocytes
(drug effects)
- Dermatologic Agents
(therapeutic use)
- HIV Infections
(drug therapy, immunology)
- Humans
- Immunocompromised Host
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Pseudolymphoma
(drug therapy, immunology)
- Skin Diseases
(drug therapy, immunology)
- Treatment Outcome
|